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Abstract  
BACKGROUND: Neurofibromatosis type 1 (NF1) is a multisystemic disorder with genetic background, 
characterised by specific cutaneous findings, skeletal dysplasias, and growth of both benign and malignant 
nervous system tumours. NF1 is caused by mutations in the NF1 gene, situated in chromosome 17q11.2, with an 
autosomal dominant pattern of inheritance and clinical manifestation of neurofibromas, malignant peripheral nerve 
sheath tumour, optic and non-optic nerve gliomas, congenital heart disease, cardiovascular and cerebrovascular 
disease and orthopaedic disorders. The incidence of gastrointestinal manifestations of NF1 is relatively low, 
compared to neurological disorders, presenting approximately in 5 to 25% of the patient, but later in life.  
CASE REPORT: We present a patient with NF1, ventricular polyposis and attentional disorders with cognitive 
phenotype, while both of her daughters also present with cutaneous manifestations of NF1.  
CONCLUSION: To the best of our knowledge, this is the first reported case of NF1 with ventricular polyposis as a 
gastrointestinal manifestation in the mother and NF1 with no signs of inner organ involvement in both of her 
daughters.  
 
 
 
 
 
 
 
 
Introduction 
 
Neurofibromatosis type 1 (NF1) is a 
multisystemic disorder with genetic background, 
characterised by specific cutaneous findings, skeletal 
dysplasias, and growth of both benign and malignant 
nervous system tumours [1][2]. NF1 is caused by 
mutations in the NF1 gene, situated in chromosome 
17q11.2, which provides instructions for making a 
protein called neurofibromin, produced in many cells, 
including nerve cells and specialised cells surrounding 
nerves (oligodendrocytes and Schwann cells) [3]. 
Neurofibromin acts as a tumour suppressor, and 
therefore, mutations in the NF1 gene lead to the 
production of a nonfunctional version of 
neurofibromin, incapable to regulate cell growth and 
division [3].  
The clinical signs and symptoms vary widely 
among affected people, usually beginning in early 
childhood [1]. One of the most typical manifestations 
represents the so-called café-au-lait spots wich can 
be single or multiple, gradually increasing in size 
[1][2]. Tumors like neurofibromas can arise along 
nerves throughout the body [2]. 
Clinical diagnosis of NF1 requires the 
presence of at least 2 of the following 7 criteria: 1) Six 
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or more café-au-lait spots or hyperpigmented macules 
=5 mm in diameter in prepubertal children and 15 mm 
postpubertal; 2) Axillary or inguinal freckles (>2 
freckles); 3) Two or more typical neurofibromas or one 
plexiform neurofibroma; 4) Optic nerve glioma; 5) Two 
or more iris hamartomas (Lisch nodules); 6) Sphenoid 
dysplasia or typical long-bone abnormalities such as 
pseudarthrosis; 7) First-degree relative (mother, 
father, sister, brother) with NF1 [2]. 
 
 
Case report 
 
A 78-year old female patient presented with 
complaints of malaise, and weakness. Attentional 
disorders with cognitive phenotype, depressive and 
suicide attentions (from 1985), spondyloarthritis, sub 
compensatory ocular peripheral syndrome, lumbar 
osteochondrosis, right-sided lumbosacral radicular 
syndrome, vertebral syndrome and gonarthrosis on 
the right (from 2003) were reported from the medical 
history as comorbidities with long-standing duration. 
Ulcus callosum gastric was also reported as 
accompanied disease and polyposis ventriculi, treated 
with resection ventriculi (Billroth II) in 2004. The 
patient had been hospitalised in 2007 with pain in the 
epigastrium and abdomen. Abdominal 
ultrasonography had established well circumscribed, 
heterogeneous solid tumour formation, measuring 4 
cm, in the pylori-antral part of the stomach, 
resembling cholelithiasis, polyp or a mesenchymal 
tumour. Further fibro gastroscopy had revealed three 
polyps, one measuring 15/10 mm, and the others 2/3 
cm, with ulcerated surface and wide basis. The 
diagnosis of hyperplasiogenic polyposis ventriculi was 
made, based on the fibro gastroscopic findings and 
histological examination. The polyps had been 
removed on a later stage.  
Clinical examination revealed multiple nodular 
and tumour-like formations, measuring from 1 to 5 cm, 
disseminated on the whole body and extremities, with 
a smooth surface and regular borders (Fig. 1a). The 
same clinical findings were observed in patient’s 
daughters, both of them with long-standing duration 
and progressive behaviour for dissemination (Fig. 
1b,c,d,e).  
The conducted paraclinical blood tests 
revealed the decreased level of erythrocytes (3.18 
10^12/l), haemoglobin (65.0 g/l), hematocrit (0.21 l/l) 
and increased plated cells count (562.0 10^9/l). 
Abdominal ultrasonography did not reveal any 
abnormalities in structure or function of the inner 
organs. Irigoscopy established hypotonic and 
hypokinetic dyskinesia of colon ascendens. 
Fibrogastroscopy findings were indicative of chronic 
active gastritis.  
The diagnosis of massive ventricular 
polyposis, associated with neurofibromatosis type I, 
affecting the patients and her daughters was made. 
All of the patients did not undergo genetic 
examination. 
 
Figure 1: 1a,b – Clinical manifestation of a 78-year-old female 
patient with NF 1 and ventricular polyposis; 1c,d,e,f – Clinical 
manifestation of NF1 in both patient’s daughters 
 
 
 
Discussion  
 
Neurofibromatoses refer to 3 genetically 
inherited disorders, which are clinically and genetically 
distinct diseases, including NF1, neurofibromatosis 
type 2 and Schwannomatosis. 
NF1 also known as Von Recklinghausen’s 
disease or peripheral neurofibromatosis, is the most 
common form of neurofibromatosis represents up to 
90% of the cases [3]. It has an autosomal dominant 
pattern of inheritance, with one mutated copy of the 
NF1 gene in each cell, which is inherited from an 
affected parent in about half of the cases [2][3]. 
Sporadic new mutations are responsible for the other 
half of the cases, with no family history of the disorder 
[2]. In contrast to most of the autosomal dominant 
conditions, two copies of the NF1 gene must be 
altered to trigger tumour formation in 
neurofibromatosis type 1, as the mutation in the 
second copy of the NF1 gene occurs during a 
person's lifetime in cells surrounding nerves [1]. It is 
not clear enough how mutations in the NF1 gene lead 
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to the other features of neurofibromatosis type 1, such 
as café-au-lait spots and learning disabilities or autism 
[4]. On the other hand, it is established that children 
and adolescents with NF1 are at increased risk for 
wide-ranging behavioural, developmental, and 
cognitive impairments, all decreasing quality of life [4]. 
Furthermore, an interesting research by 
Jonas RK. et al (2017) observed significantly reduced 
neural activity across multiple brain regions involved 
in higher-order semantic processing and motivation in 
patients with NF1 relative to controls and atypical age-
associated changes in neural activity in patients with 
NF1, such that during risk-taking, neural activity 
tended to decrease with age in controls, whereas it 
tended to increase with age in patients with NF1 [5]. 
The more commonly encountered manifestations of 
NF 1 include plexiform neurofibromas, malignant 
peripheral nerve sheath tumour (MPNST), optic and 
non-optic nerve gliomas, congenital heart disease, 
cardiovascular and cerebrovascular disease, and 
orthopaedic disorders [1][3]. Other signs and 
symptoms may include high blood pressure, bone 
abnormalities, lisch nodules, learning disabilities and 
attention deficit, hyperactivity disorder; autism 
spectrum disorder, larger than average head size, 
short stature [1]. The incidence of gastrointestinal 
manifestations of NF 1 is relatively low, compared to 
neurological disorders, presenting approximately in 5 
to 25% of the patient, but later in life [3]. 
Gastrointestinal symptoms include visceral 
neurogenic tumours, gastrointestinal stromal tumour 
and neuroendocrine tumours and clinical signs could 
include abdominal pain, dyspepsia, vomiting, 
anaemia, melena, hematemesis, hematochezia, 
intussusception, volvulus, small bowel obstruction, 
fever and abdominal mass [3].  
To the best of our knowledge, this is the first 
reported case of NF1 in a three-member family, with 
different clinical manifestation and associated 
symptoms, including ventricular polyposis in the 
mother and no signs of inner organ involvement in her 
daughters.  
Although there is no general cure for NF1, 
surgery can be used to remove tumours that cause 
pain or a loss of function, press on vital structures, 
obstruct vision, or grow rapidly [1][2]. Annual 
examinations and screening are mandatory, as the 
patient's morbidity is a result of the associated 
complications [3].  
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